Latest Fovea Stories
In 2011 — to the consternation of women everywhere — a systematic review of randomized clinical trials showed that routine mammography was of little value to younger women at average or low risk of breast cancer.
Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World.
Vision scientists have identified a key player in macular degeneration (MD), raising hope for a treatment for the currently incurable blinding disease.
Adaptive optics technology likely to spur sight-saving interventions, usher in new era of eye disease research, diagnosis and treatment.
ST. LOUIS, March 16, 2011 /PRNewswire/ -- ZeaVision, LLC announced that its Zeaxanthin-based nutraceutical, EyePromise Restore, has been improved with a 25% increase in Omega 3's and the addition of Vitamin D3.
Seahorses are helping scientists gain new understanding about how detailed vision develops â€“ in research which may open a way to restore sight in people with age-related blinding diseases.
ST. LOUIS, July 7 /PRNewswire/ -- ZeaVision's EyePromiseÂ® nutraceutical products are unique science-based formulations designed to support eye health.
GENEVA, May 20 /PRNewswire/ -- Valensa International (Eustis, FL USA) announced the introduction of a new eye health formulation that combines the leading eye health ingredients in a single, easy-to-use product.
PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis.
Three young adults who received gene therapy for a blinding eye condition remained healthy and maintained previous visual gains one year later, according to an August online report in Human Gene Therapy.
- Withering but not falling off, as a blossom that persists on a twig after flowering.